Number of pages: 100 | Report Format: PDF | Published date: March 22, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global fragment-based drug discovery market was valued at US$ 418.8 million in 2022 and is expected to register a revenue CAGR of 8.6% to reach US$ 880.1 million by 2031.
Fragment-based Drug Discovery Market Fundamentals
Fragment-based drug discovery (FBDD) tests low-molecular-weight molecules against clinically relevant macromolecular targets. These chemicals serve as beginning points for therapeutic development. Throughout the last 15 years, FBDD has evolved and increased in popularity. Finding and developing new drugs is laborious and complex, requiring a substantial commitment of time, money, and resources. It is estimated that it takes an average of 10 to 12 years to get from establishing the initial proof-of-concept to the commercial launch.
Meanwhile, a small percentage of early-stage treatment candidates can get through preclinical testing and into the clinical review. Even fewer candidates in the clinical stage receive commercialization approval. The entire cost of pharmaceutical and biotechnology R&D has been rising over time due to the increasing complexity of drug development research. The market is currently under immense pressure not just to figure out how to reduce the risks of fragment-based drug research initiatives failing. FBDD has gained importance and interest over the past few decades, particularly in the pharmaceutical industry. The benefits of biophysical and biochemical techniques are combined in FBDD to identify small molecules binding to a particular target. Fragment hits offer exciting and simple beginning points for creating drug leads if chosen after careful evaluation. Using a variety of different biophysical techniques can help with initial identification. A small library of low molecular weight compounds is often screened as the first step in FBDD to see if they bind to a specific target. A low level of complexity is the main benefit of fragment-based drug discovery. The demand for these methods has increased due to the significant time and cost savings of integrating novel approaches into fragment-based drug development methodologies.
Biophysical approaches become increasingly important as FBDD is used to find weaker inhibitors. These methods can assess the inside binding of compounds with low binding affinities for fragments. FBDD has been demonstrated to have several advantages, including the ability to produce hits with better physiochemical qualities and a cost advantage. In this perspective, fragment-based library screens were the source of three commercially available medications: Vemurafenib (ZELBORAF®), Venetoclax (VENCLEXTA®), and Erdafitinib (BALVERSATM). Clinical trials are underway for about 40 candidates identified by the FBDD. More than 50% of current discovery efforts are estimated to use the FBDD strategy, which uses biophysical methods, such as nuclear magnetic resonance and X-ray crystallography. Additionally, the availability of customized fragment collections created for specific biological targets is anticipated to speed up the search for effective drug leads for harder-to-reach targets such as protein-protein interactions and allosteric sites on enzymes.
Fragment-based Drug Discovery Market Dynamics
A potent technique for creating powerful small-molecule compounds starting with fragments that bind weakly to targets is known as FBDD, which outperforms high-throughput screening campaigns in several ways, making it a desirable approach for target-based drug development. This method has created powerful substances and inhibitors of numerous targets. The increasing prevalence of numerous chronic conditions, rising healthcare costs, and the upcoming patent expirations of several well-known medications worldwide all significantly contribute to the revenue growth of the worldwide fragment-based drug discovery market. The prevalence of diseases, such as cancer, diabetes, respiratory illnesses, cardiovascular diseases, and neurological disorders, is increasing worldwide, fueling the demand for novel and cutting-edge medications. The pharmaceutical business, which is expanding tremendously due to the rapid development of biopharmaceuticals, is anticipated to dominate the fragment-based drug discovery market in the years to come. Due to increased government and corporate funding for the creation of novel medications to treat chronic diseases, the biopharmaceutical industry is expanding quickly.
Cancer, diabetes, and cardiovascular diseases are becoming more prevalent due to changing lifestyles, altering consumption patterns, bad eating habits, rising pollution levels, and physical inactivity. The International Organization for Research on Cancer estimates there will be around 19.3 million new cancer cases and approximately 10 million cancer-related deaths in 2020. By 2045, the World Diabetes Federation predicts that 783 million people worldwide will have diabetes. Furthermore, type 1 diabetes affects about 1.2 million kids and teenagers. The greatest cause of death worldwide, according to the World Health Organization, is cardiovascular disease, which causes almost 18 million deaths annually.
However, the most common component of fragment screening, which has been found to have decreased potency in some compounds, is likely to have a significant negative impact on the demand for the fragment-based drug discovery market. Numerous end-users are discouraged from using this method since the medications produced are not as potent as needed.
Fragment-based Drug Discovery Market Ecosystem
The global fragment-based drug discovery market is analyzed from three perspectives: technique, end-user, and region.
Fragment-based Drug Discovery Market by Technique
Based on the technique, the global fragment-based drug discovery market is segmented into biophysical and non-biophysical techniques. The biophysical technique segment is further sub-segmented into NMR spectroscopy, DSF assay, fluorescence polarization, isothermal titration calorimetry, X-ray crystallography, SPR, biolayer interferometry, mass spectrometry, capillary electrophoresis, and others.
The biophysical technique segment accounted for the largest revenue share of the global fragment-based drug discovery market in 2022. In fragment-based drug discovery, biophysical approaches are important to hit finding and validation. For the inexperienced user, the three most often utilized technologies, thermal shift, surface plasmon resonance, and nuclear magnetic resonance, might be challenging—the poor affinities displayed by fragments in fragment-based drug development present major screening difficulties. The weak affinity exhibiting problem is tackled using biophysical techniques. However, there is no clear agreement on the sequence of techniques most suitable for identifying fragment hits that ultimately convert into bound X-ray structures and provide reliable starting points for synthesis. An integrated biophysical approach is benchmarked for fragment screening and validation against Mycobacterium tuberculosis pantothenate synthetase. Thermal shift technology was used for a 1,250-fragment library primary screen, followed by a one-dimensional NMR spectroscopy secondary screen (water ligand observed gradient spectroscopy and saturation transfer difference binding experiments), and isothermal titration calorimetry and X-ray crystallography final strike validation.
Fragment-based Drug Discovery Market by End-user
Based on the end-user, the global fragment-based drug discovery market is segmented into biopharmaceutical companies, CROs, and academic and research institutions.
The biopharmaceutical companies segment accounted for the largest revenue share of the global fragment-based drug discovery market in 2022. FBDD methods have become increasingly well-liked in recent years. They offer a wide range of applications in the biopharmaceutical industry. This comprises big businesses, academic institutions, and CROs. These methods have dramatically increased the success rate of synthesis over traditional screening methods, which has greatly aided in the development of chemical series with properties resembling those of lead. Techniques for FBDD have also been quite effective in identifying chemical motifs from various targets. All these elements are anticipated to make FBDD profitable for biopharmaceutical facilities due to leading pharmaceutical and biotechnology businesses investing more money in creating new medicines in the fragment-based drug discovery market. The growing elderly population and incidence of chronic diseases are driving up demand for a wide range of cutting-edge medications. The global rise in drug demand has stimulated the market for fragment-based drug discovery. Also, the biopharmaceutical industry’s explosive rise has greatly aided market expansion.
The CROs segment is anticipated to be the most prominent segment throughout the forecast period. The demand for CRO services among pharmaceutical companies, which is growing, has led to a greater global penetration of small and medium-sized CROs, which is significantly accelerating the expansion of the fragment-based drug discovery market. The most common activity in the fragment-based drug development process is research, and small and medium pharmaceutical businesses with limited financial resources frequently hire CROs, which helps this market revenue growth.
Fragment-based Drug Discovery Market by Region
Based on the region, the global fragment-based drug discovery market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global fragment-based drug discovery market in 2022. In terms of global spending on research and development, the U.S. accounts for the largest revenue share in North America. Furthermore, most recently developed new pharmaceuticals are protected by U.S. patents. Also, the rising frequency of chronic diseases has increased the demand for cutting-edge and novel medications, which has supported the expansion of the drug discovery market in North America. In the U.S., around half of the population has one or more chronic illnesses. The growing demand for biologics is also boosting market revenue growth. A surge in investments by drug research businesses, sizable grants from the U.S. Government, a strong presence of significant drug development companies, a well-developed healthcare infrastructure, and an increase in chronic diseases are a few of the elements influencing the expansion of the fragment-based drug discovery market in this region.
The most lucrative market in the upcoming years is predicted to be in Asia Pacific. This can be attributable to the region having a large number of CROs. A further factor driving demand for biologic products is the significant investments made in the pharmaceutical sector by nations, such as South Korea, India, and China. Also, as older individuals are more prone to chronic ailments, the growing geriatric population is anticipated to result in higher drug demand in the near future.
Fragment-based Drug Discovery Market Competitive Landscape
The global fragment-based drug discovery market has high competition due to new product releases, mergers, and acquisitions. The main development approaches that many organizations are targeting include the introduction of novel products, obtaining approval for those products, and participating in additional activities such as awareness projects. Also, the market regarded alliances, acquisitions, and countless other forms of cooperation as superior growth strategies. These initiatives have increased the likelihood of successful future growth possibilities due to the growing global market demand for fragment-based drug discovery.
Notable market participants include:
Fragment-based Drug Discovery Market Strategic Developments
Fragment-based drug discovery (FBDD) is a powerful method for developing potent small-molecule compounds from fragments binding weakly to targets.
The increased prevalence of chronic diseases and the surge in the development of new drugs drive the global fragment-based drug discovery market.
The weak efficiency level of fragment screening is the most important factor inhibiting the market’s revenue growth.
Key companies operating the global fragment-based drug discovery market are Astex Pharmaceuticals, Alveus Pharmaceuticals Pvt. Ltd., Beactica AB, Charles River Laboratories International Inc., and Crown Biosciences Inc.
The global fragment-based drug discovery market is expected to grow at a revenue CAGR of 8.6% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain